A disease that still kills hundreds of thousands each year
Malaria kills more than 600,000 people annually, the vast majority of them children under five in sub-Saharan Africa. Despite decades of global effort, a highly effective vaccine has remained elusive.
New vaccines targeting the early stages of the malaria parasite's life cycle have made progress. But the parasite is clever — it changes its surface proteins at different stages, making it hard for a single vaccine to stop it completely.
Why a blood-stage vaccine matters
Existing malaria vaccines approved in recent years focus on blocking the parasite before it enters the bloodstream — at the pre-erythrocytic stage (before the parasite invades red blood cells). The new candidate tested in this study takes a different approach: it targets the parasite after it enters the blood.
The antigen it uses is called RH5 — a protein the malaria parasite absolutely cannot do without when trying to break into red blood cells. Because RH5 has a highly consistent structure across different strains of the parasite, it's a promising target. Blocking RH5 is like changing the lock on the door the parasite needs to enter.
Old approach vs. new angle
Current frontline malaria vaccines, like RTS,S and R21, work well but are not fully protective. A vaccine that hits the parasite at a later stage of its life cycle could complement those tools — potentially blocking infections that slip past early-stage vaccines.
But here's the practical challenge: getting vaccines to remote, high-burden communities is hard. Dose-sparing strategies — where a smaller final dose works just as well — could allow the same amount of vaccine to protect more people.
What the trial tested
This Phase 1a clinical trial enrolled 24 healthy adults in the United Kingdom who had never been exposed to malaria. Participants received three shots over six months. One group received 10 micrograms of the RH5.1 protein for all three shots. The other received 50 micrograms for the first two shots and a smaller 10-microgram final dose.
Both groups also received 50 micrograms of Matrix-M adjuvant (an immune-boosting ingredient also used in some flu and COVID vaccines) with each shot.
Both dosing regimens produced nearly identical immune responses. Peak antibody levels, the strength of those antibodies against actual parasites in lab tests, how tightly the antibodies bound to their target, and how long protection lasted — all were statistically similar between the two groups.
That means cutting the final booster dose from 50 micrograms to 10 micrograms did not meaningfully reduce the immune response.
This finding suggests that careful dose optimization — not just injecting as much as possible — may be the smarter path forward for vaccine development.
The safety picture
The vaccine was well-tolerated. The most common side effects were injection-site pain, muscle aches, and fatigue in the days following vaccination. No serious adverse events were reported in any participant over the full year of follow-up.
Where the field stands
This study fits into a broader research strategy aimed at building a multi-antigen, multi-stage malaria vaccine — one that attacks the parasite at several points in its life cycle simultaneously. The RH5.1/Matrix-M combination is now moving into Phase 2b testing in malaria-endemic regions of West Africa, where researchers will be able to measure protection against real-world infection.
If you live in or travel to malaria-endemic regions, this vaccine is not yet available. It is still in early clinical development. The most effective current prevention tools remain insecticide-treated bed nets, antimalarial medications for travelers, and for eligible children in endemic areas, the approved RTS,S or R21 vaccines.
Limitations worth knowing
This was a very small trial — just 24 participants — conducted in malaria-naive adults in the UK. Small trials in low-exposure populations tell researchers a lot about safety and immune responses, but they cannot predict how the vaccine will perform in children in Africa who face repeated malaria exposure from birth. The populations that need this vaccine most have not yet been included in testing.
What comes next
Phase 2b trials currently underway in Burkina Faso will be far larger and will measure actual protection against malaria infection and disease. If those results are encouraging, the vaccine could advance to larger Phase 3 efficacy trials. That process typically takes several more years. The path is long, but the science is moving with renewed urgency.
